I agree that this site is using cookies. You can find further informations here.
X
Limón-Mirón, María Luisa
44  results:
Search for persons X
?
1

A Cross-Sectional Validation Study of Camry EH101 versus JA..:

Jiménez-Sánchez, Andrés ; Pereira-Cunill, José Luis ; Limón-Mirón, María Luisa...
Nutrients.  16 (2024)  12 - p. 1824 , 2024
Link: https://doi.org/10.3390/..
 
?
2

Nivolumab plus relatlimab in patients with previously treat..:

Overman, Michael J ; Gelsomino, Fabio ; Aglietta, Massimo...
Journal for ImmunoTherapy of Cancer.  12 (2024)  5 - p. e008689 , 2024
Link: https://doi.org/10.1136/..
 
?
3

Evolution of RAS Mutations in Cell-Free DNA of Patients wit..:

Valladares-Ayerbes, Manuel ; Garcia-Alfonso, Pilar ; Muñoz Luengo, Jorge...
Cancers.  14 (2022)  24 - p. 6075 , 2022
Link: https://doi.org/10.3390/..
 
?
4

Bacteriemia causada por Leuconostoc spp. en una paciente co..:

Limón Mirón, María Luisa ; Conde, Manuel Chaves ; Moreno Nogueira, José Andrés.
Revista de Oncología.  3 (2001)  3 - p. 159-160 , 2001
Link: https://doi.org/10.1007/..
 
?
5

The McCAVE Trial: Vanucizumab plus mFOLFOX-6 Versus Bevaciz..:

Bendell, Johanna C. ; Sauri, Tamara ; Gracián, Antonio Cubillo...
The Oncologist.  25 (2019)  3 - p. e451-e459 , 2019
Link: https://doi.org/10.1634/..
 
?
6

Tumor Response and Symptom Palliation from RAINBOW, a Phase..:

Cascinu, Stefano ; Bodoky, György ; Muro, Kei...
The Oncologist.  26 (2020)  3 - p. e414-e424 , 2020
Link: https://doi.org/10.1002/..
 
?
7

The McCAVE Trial : Vanucizumab plus mFOLFOX-6 Versus Bevaci..:

Bendell, Johanna C ; Sauri, Tamara ; Gracian, Antonio Cubillo...
Oncologist.  , 2020
Link: https://hdl.handle.net/2..
 
?
8

Randomized, double‐blind, phase two study of ruxolitinib pl..:

Fogelman, David ; Cubillo, Antonio ; García‐Alfonso, Pilar...
Cancer Medicine.  7 (2018)  11 - p. 5382-5393 , 2018
Link: https://doi.org/10.1002/..
 
?
9

Phase II study of the antibody-drug conjugate TAK-264 (MLN0..:

Almhanna, Khaldoun ; Miron, Maria Luisa Limon ; Wright, David...
Investigational New Drugs.  35 (2017)  2 - p. 235-241 , 2017
Link: https://doi.org/10.1007/..
 
?
10

Evolution of RAS Mutations in Cell-Free DNA of Patients wit..:

Valladares-Ayerbes, Manuel ; Garcia-Alfonso, Pilar ; Muñoz Luengo, Jorge...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9776941/.  , 2022
Link: http://www.ncbi.nlm.nih...
 
?
11

External validity of clinical trials with diverse trastuzum..:

Jimenez Fonseca, Paula ; Carmona Bayonas, Alberto ; Martínez Torron, Alba...
Reproducció del document publicat a: https://doi.org/10.1177/17588359211019672.  , 2021
Link: http://hdl.handle.net/24..
 
?
12

The McCAVE Trial: Vanucizumab plus mFOLFOX‐6 Versus Bevaciz..:

Bendell, Johanna C ; Sauri, Tamara ; Gracián, Antonio Cubillo...
Reproducció del document publicat a: https://doi.org/10.1634/theoncologist.2019-0291.  , 2019
Link: http://hdl.handle.net/24..
 
?
13

Evolution of RAS Mutations in Cell-Free DNA of Patients wit..:

Manuel Valladares-Ayerbes ; Pilar Garcia-Alfonso ; Jorge Muñoz Luengo...
Cancer Biomarkers.  , 2022
Link: https://doi.org/10.3390/..
 
?
14

Evolution of RAS Mutations in Cell-Free DNA of Patients wit..:

Manuel Valladares-Ayerbes ; Pilar Garcia-Alfonso ; Jorge Muñoz Luengo...
https://www.mdpi.com/2072-6694/14/24/6075.  , 2022
Link: https://doi.org/10.3390/..
 
?
15

Randomized, double‐blind, phase two study of ruxolitinib pl..:

David Fogelman ; Antonio Cubillo ; Pilar García‐Alfonso...
https://doi.org/10.1002/cam4.1703.  , 2018
Link: https://doi.org/10.1002/..
 
1-15